JP2011522796A - 抗ウイルス細胞透過性ペプチド - Google Patents

抗ウイルス細胞透過性ペプチド Download PDF

Info

Publication number
JP2011522796A
JP2011522796A JP2011508615A JP2011508615A JP2011522796A JP 2011522796 A JP2011522796 A JP 2011522796A JP 2011508615 A JP2011508615 A JP 2011508615A JP 2011508615 A JP2011508615 A JP 2011508615A JP 2011522796 A JP2011522796 A JP 2011522796A
Authority
JP
Japan
Prior art keywords
peptide
seq
amino acids
amino acid
nyad
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011508615A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011522796A5 (https=
Inventor
アシム クマール デブナス，
ホンタオ シャン，
フランセスカ カレリ，
Original Assignee
ニューヨーク ブラッド センター， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューヨーク ブラッド センター， インコーポレイテッド filed Critical ニューヨーク ブラッド センター， インコーポレイテッド
Publication of JP2011522796A publication Critical patent/JP2011522796A/ja
Publication of JP2011522796A5 publication Critical patent/JP2011522796A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011508615A 2008-05-06 2009-05-05 抗ウイルス細胞透過性ペプチド Pending JP2011522796A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5095508P 2008-05-06 2008-05-06
US61/050,955 2008-05-06
PCT/US2009/042913 WO2009137532A1 (en) 2008-05-06 2009-05-05 Antiviral cell penetrating peptides

Publications (2)

Publication Number Publication Date
JP2011522796A true JP2011522796A (ja) 2011-08-04
JP2011522796A5 JP2011522796A5 (https=) 2012-02-02

Family

ID=40957984

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011508615A Pending JP2011522796A (ja) 2008-05-06 2009-05-05 抗ウイルス細胞透過性ペプチド

Country Status (6)

Country Link
US (2) US8324153B2 (https=)
EP (1) EP2283033A1 (https=)
JP (1) JP2011522796A (https=)
AU (1) AU2009244400B2 (https=)
CA (1) CA2725227A1 (https=)
WO (1) WO2009137532A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022535142A (ja) * 2019-06-07 2022-08-04 ザ キュレイターズ オブ ザ ユニバーシティ オブ ミズーリ Ｈｉｖカプシドの阻害のためのペプチド阻害剤

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2073829B1 (en) * 2006-10-05 2012-06-20 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
US8937154B2 (en) 2006-10-05 2015-01-20 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
DK2118123T3 (en) 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabilized p53 peptides and uses thereof
US8592377B2 (en) 2007-03-28 2013-11-26 President And Fellows Of Harvard College Stitched polypeptides
WO2009137532A1 (en) * 2008-05-06 2009-11-12 New York Blood Center Antiviral cell penetrating peptides
ES2711526T3 (es) 2010-08-13 2019-05-06 Aileron Therapeutics Inc Macrociclos peptidomiméticos
WO2012137036A1 (en) * 2011-04-04 2012-10-11 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
US20140213502A1 (en) * 2011-04-29 2014-07-31 United States Department of Health and Human Services Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc TRIAZOL AND THIOETHER-COUPLED PEPTIDOMIMETIC MACROCYCLES
BR112014020103A2 (pt) 2012-02-15 2018-10-09 Aileron Therapeutics, Inc. macrociclos peptidomiméticos
WO2014053880A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
AU2015320545C1 (en) 2014-09-24 2020-05-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
CN105622732B (zh) * 2014-10-30 2019-10-25 中国科学院武汉病毒研究所 猴病毒40衣壳蛋白vp1在作为细胞穿膜蛋白中的应用
MX387665B (es) 2014-12-24 2025-03-18 Aadigen Llc Péptidos, complejos, moléculas de carga y nanopartículas que contienen los mismos.
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2017044633A1 (en) 2015-09-10 2017-03-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of mcl-1
EP3724216A1 (en) 2017-12-15 2020-10-21 Dana Farber Cancer Institute, Inc. Stabilized peptide-mediated targeted protein degradation
US11952432B2 (en) 2018-02-07 2024-04-09 Dana-Farber Cancer Institute, Inc. Cell-permeable stapled peptide modules for cellular delivery
WO2021178714A2 (en) * 2020-03-04 2021-09-10 Dana-Farber Cancer Institute, Inc. ANTIVIRAL STRUCTURALLY-STABILIZED SARS-CoV-2 PEPTIDES AND USES THEREOF
CA3179872A1 (en) * 2020-04-22 2021-10-28 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stabilized ace2 helix 1 peptides and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040744A1 (de) * 1997-03-10 1998-09-17 Roche Diagnostics Gmbh Verfahren zur simultanen bestimmung von hiv-antigenen und hiv-antikörpern
WO2001090197A1 (en) * 2000-05-26 2001-11-29 The Australian National University Synthetic peptides and uses therefore
WO2008045238A2 (en) * 2006-10-05 2008-04-17 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187548B1 (en) 1993-05-23 2001-02-13 Rhone-Poulenc Rorer Pharmaceuticals Inc. Methods using human calcium sensor protein, fragments thereof and DNA encoding same
US6239270B1 (en) 1993-05-24 2001-05-29 Rhone-Poulenc Rorer S.A. Nucleic acids encoding human calcium sensor protein
US6790950B2 (en) 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
HK1045856A1 (zh) 1999-04-09 2002-12-13 法玛西雅厄普约翰美国公司 抗细菌疫苗组合物
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US20020124273A1 (en) 2000-10-17 2002-09-05 Jean-Marc Roch Protein-protein interactions in neurodegenerative diseases
ES2586387T3 (es) 2003-11-05 2016-10-14 Dana-Farber Cancer Institute, Inc. Péptidos alfa helicoidales adecuados para activar o inhibir la muerte celular
US20100151483A1 (en) 2006-07-13 2010-06-17 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in signaling pathways
US20100159477A1 (en) 2006-07-13 2010-06-24 Peter Hornbeck Reagents for the detection of protein phosphorylation in signaling pathways
JP2010502765A (ja) 2006-09-11 2010-01-28 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ キュプレドキシン由来ペプチドの修飾及びそれを使用する方法
US8937154B2 (en) 2006-10-05 2015-01-20 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
DK2118123T3 (en) 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabilized p53 peptides and uses thereof
JP5078401B2 (ja) * 2007-03-27 2012-11-21 株式会社Ａｄｅｋａ 防水シート
CA2700925C (en) 2007-09-26 2016-08-23 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
EP2247606B1 (en) 2008-01-23 2019-08-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of viral infections
WO2009137532A1 (en) * 2008-05-06 2009-11-12 New York Blood Center Antiviral cell penetrating peptides
EP3401684B1 (en) 2008-10-10 2022-03-16 Dana Farber Cancer Institute, Inc. Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040744A1 (de) * 1997-03-10 1998-09-17 Roche Diagnostics Gmbh Verfahren zur simultanen bestimmung von hiv-antigenen und hiv-antikörpern
WO2001090197A1 (en) * 2000-05-26 2001-11-29 The Australian National University Synthetic peptides and uses therefore
WO2008045238A2 (en) * 2006-10-05 2008-04-17 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022535142A (ja) * 2019-06-07 2022-08-04 ザ キュレイターズ オブ ザ ユニバーシティ オブ ミズーリ Ｈｉｖカプシドの阻害のためのペプチド阻害剤
US12590125B2 (en) 2019-06-07 2026-03-31 The Curators Of The University Of Missouri Peptide inhibitors for the inhibition of HIV capsid

Also Published As

Publication number Publication date
WO2009137532A1 (en) 2009-11-12
US20090281041A1 (en) 2009-11-12
US20130059776A1 (en) 2013-03-07
CA2725227A1 (en) 2009-11-12
EP2283033A1 (en) 2011-02-16
AU2009244400A1 (en) 2009-11-12
US8933019B2 (en) 2015-01-13
AU2009244400A2 (en) 2010-11-11
US8324153B2 (en) 2012-12-04
AU2009244400B2 (en) 2012-12-20

Similar Documents

Publication Publication Date Title
AU2009244400B2 (en) Antiviral cell penetrating peptides
JP2011522796A5 (https=)
ES2387827T3 (es) Péptidos antivirales helicoidales, de pequeño tamaño, terapéuticos estabilizados
JP2010209097A (ja) Ｈｉｖ感染のペプチド誘導体融合阻害剤
CN106749558B (zh) 广谱抑制hiv的脂肽、其衍生物、其药物组合物及其用途
AU2017410525B2 (en) Potent HIV inhibiting lipopeptide, derivative thereof, pharmaceutical composition thereof and use thereof
US8937154B2 (en) Stabilized therapeutic small helical antiviral peptides
EP2291392B1 (en) Bifunctional molecules for inhibiting hiv entry
US9233138B2 (en) Compositions for promoting HIV-1 virolysis and methods using same
US20060281673A1 (en) Novel peptide inhibitor of hiv fusion that disrupts the internal trimeric coiled-coil of gp41
WO2018141089A1 (zh) 广谱抑制hiv的脂肽、其衍生物、其药物组合物及其用途
Spensiero Design and synthesis of new integrase inhibitors
CA2766417A1 (en) Stabilized therapeutic small helical antiviral peptides
AU2012200580A1 (en) Stabilized therapeutic small helical antiviral peptides
Zhang Interaction-mediating sequences within class I viral fusion glycoproteins: their roles in viral infection and in applications
Simin Interaction-Mediating Sequences within Class I Viral Fusion Glycoproteins: Their Roles in Viral Infection and in Applications
WO2005068492A2 (en) Peptide inhibitors of retroviral integrase useful for the treatment of retroviral infection
Bailey The mechanism of HIV-1 virolytic inactivation by Env-targeting peptide triazole thiols
OA19487A (en) Potent HIV inhibiting lipopeptide, derivative thereof, pharmaceutical composition thereof and use thereof.
VOTTELER et al. Use of Synthetic Peptides for Structural and Functional Analyses of Viruses Like HIV
Poe Bimolecular fluorescence complementation reveals that HIV-1 Nef oligomerization is essential for CD4 downregulation and viral replication

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130725

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131219